Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PFIZER, INC.

(PFE)
  Report
Real-time Estimate Cboe BZX  -  01:03 2022-09-29 pm EDT
44.27 USD   -0.36%
08:39aBiohaven's ALS drug fails to meet study goals
RE
09/28Indonesia approves first home-grown COVID vaccine for emergency use - media
RE
09/28Merck agrees to allow Sinopharm to sell molnupiravir COVID drug in China
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

University of Bristol : Increase in non-COVID-19 respiratory infections predicted this winter

08/10/2022 | 07:08am EDT

University of Bristol - An increase in the number of non-COVID-19 respiratory infections should be expected this winter, say scientists. The warning comes following the results of a new study, published in The Lancet Regional Health - Europe, which found that over 55% of respiratory disease hospitalisations during the pandemic's peak were caused by non-SARS-CoV-2 infections.

The University Bristol-led study funded and conducted in collaboration with Pfizer Inc., as part of AvonCAP, is the first to compare the number of hospitalisations from respiratory disease infections caused by COVID-19 and non-SARS-CoV-2 infections.

Using data from 135,014 hospitalisations from two large hospitals in Bristol between August 2020 and November 2021, researchers identified 12,557 admissions attributable to acute Lower Respiratory Tract Disease (aLRTD) with patients admitted with signs or symptoms of respiratory infections including cough, fever, pleurisy, or a clinical or radiological aLRTD diagnosis. Of these, 12,248 (98%) patients, comprising mainly older adults, consented to participate in the study.

Following further analysis, the team show that of the 12,248 aLRTD hospitalisations, 55% (6,909) were due to infection with no evidence of SARS-CoV-2, while confirmed SARS-CoV-2 infection only accounted for 26% (3,178) of respiratory infections. The remaining 17% (2,161) were due to infection with no infective cause.

Adam Finn, Professor of Paediatrics at the University of Bristol, Director of the Bristol Vaccine Centre at Bristol Medical School and lead of Bristol UNCOVER (Bristol COVID Emergency Research Group), said: 'What is really surprising from our results is just how much other non-COVID respiratory infections there was during this time, other infections clearly didn't just disappear and despite significant public health measures, including both vaccination and non-pharmaceutical intervention such as masks, our findings show there was still a high incidence of non-COVID-19 disease causing hospitalisations alongside COVID-19 patients.'

Dr Catherine Hyams, Post-Doctoral Clinical Research Fellow, Principal Investigator for the AvonCAP study and one of the study's lead authors at the University of Bristol, added: 'Our results really highlight not only the huge burden of respiratory infection on the NHS and other healthcare systems, but also how bad things may get this winter. It is therefore essential that appropriate healthcare planning and resource allocation is undertaken to care for patients with respiratory conditions, in addition to implementation of public health measures to reduce respiratory disease burden and improve patient outcomes.'

The study is part of AvonCAP, an ongoing collaborative surveillance project funded by Pfizer Inc., which records detailed information on every adult patient admitted to Bristol's two large NHS hospitals with symptoms, signs and/or X-ray evidence of acute disease in the lungs.

Paper

'Incidence of community acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: a prospective cohort study' by A Finn et al. in The Lancet Regional Health - Europe

Further information

COVID-19 research outputs

A full list of University of Bristol research outputs relating to the COVID-19 pandemic is available online.

Bristol UNCOVER Group

In response to the COVID-19 crisis, researchers at the University of Bristol formed the Bristol COVID Emergency Research Group (UNCOVER) to pool resources, capacities and research efforts to combat this infection.

Bristol UNCOVER includes clinicians, immunologists, virologists, synthetic biologists, aerosol scientists, epidemiologists and mathematical modellers and has links to behavioural and social scientists, ethicists and lawyers.

Follow Bristol UNCOVER on Twitter at: twitter.com/BristolUncover

For more information about the University of Bristol's coronavirus (COVID-19) research priorities visit: http://www.bristol.ac.uk/research/impact/coronavirus/research-priorities/

Elizabeth Blackwell Institute is supporting COVID research

Find out more about the Institute's COVID-19 research looking into five key areas: virus natural history, therapeutics and diagnostics research; epidemiology; clinical management; vaccines; and ethics and social science.

Support our COVID-19 research

Bristol's researchers are part of a global network of scientists responding urgently to the challenge of the coronavirus pandemic.

Find out how you can support their critical work

About the AvonCAP study

The AvonCAP (community-acquired pneumonia) study from Bristol is a prospective test negative case control study of adult respiratory infection and vaccine-preventable pneumococcal disease in the context of COVID-19 admitted to two large NHS hospitals. The study is conducted in collaboration with and funded by Pfizer Inc. The study funder had no role in data collection, but collaborated in study design, data interpretation and analysis, and writing this manuscript.

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about PFIZER, INC.
08:39aBiohaven's ALS drug fails to meet study goals
RE
09/28Indonesia approves first home-grown COVID vaccine for emergency use - media
RE
09/28Merck agrees to allow Sinopharm to sell molnupiravir COVID drug in China
RE
09/28Pfizer, BioNTech Seeks European Nod for COVID Vaccine Booster for Children 5 to 11
MT
09/28Pfizer, BioNTech File European Medicines Agency Application for Omicron Booster Dose fo..
MT
09/28Indonesia approves first home-grown COVID vaccine for emergency use - media
RE
09/27Japan's Shionogi says COVID pill reaches endpoint in Phase III trial
RE
09/27IDT Australia Names Acting CFO
MT
09/27Biohaven Pharmaceutical's Acquisition by Pfizer Likely to Close Oct. 3
MT
09/27Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formaliz..
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 739 M - -
Net cash 2022 10 262 M - -
P/E ratio 2022 7,85x
Yield 2022 3,65%
Capitalization 249 B 249 B -
EV / Sales 2022 2,35x
EV / Sales 2023 2,92x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 44,43 $
Average target price 55,75 $
Spread / Average Target 25,5%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-24.76%249 357
JOHNSON & JOHNSON-2.75%437 390
ELI LILLY AND COMPANY12.63%317 719
ROCHE HOLDING AG-14.15%273 173
ABBVIE INC.6.79%255 667
NOVO NORDISK A/S3.96%224 155